Financial liabilities (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
| Disclosure of financial liabilities [abstract] |
|
| Disclosure of financial liabilities breakdown |
Financial liabilities break down as follows: | | | | | | (amounts in thousands of euros) | | | | | | | | | | | | Kreos & Claret bond loans | | | | | | | | | | | | | | | | | | | | | | | | Kreos & Claret convertible notes (OCABSA) | | | | | | | | | | | | Kreos & Claret minimal return indemnifications | | | | | | | | | | | | Conditional advances Bpifrance | | | | | | | | | | | | Other financial liabilities | | | | | | Total non-current financial liabilities | | | | | | | | | | | | Kreos & Claret bond loans | | | | | | | | | | | | | | | | | | | | | | | | Heights convertible notes | | | | | | | | | | | | Conditional advances Bpifrance | | | | | | Other financial liabilities | | | | | | | | | | | | | | | | | | Total current financial liabilities | | | | | | Total financial liabilities | | | | | |
|
| Disclosure of main data and assumptions used for the measurement of other equity instruments |
The fair value of the BSAs was determined at grant date using the Black Scholes model, with the following assumptions: | | | | | | | | | | | | | | | | | | | FAIR VALUE OF THE UNDERLYING SHARE | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | FAIR VALUE OF THE UNDERLYING SHARE | | | | | | | | | | | AGA 2023-1 (Tranches 1-4) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
The fair value of the Minimum Return Indemnifications was measured using the following assumptions: | | | | | Tranche B Minimum Return Indemnification (issued in March 2024) | | | | | Final redemption scenario probability | | | | | | | | | | | | | | | Probability-weighted present value of shortfall payment (in thousands of €) | | 1,959 (Final redemption) 68 (Tender offer) | | 2,635 (Final redemption) 136 (Tender offer) | Probability-weighted fair value of tranche A-B warrants with MRI (in thousands of €) | | | | | Probability-weighted fair value of tranche A-B warrants without MRI (in thousands of €) | | | | | Total fair value of MRI (in thousands of €) | | 1,615 (Final redemption, i.e. a+b-c) 68 (Tender offer) | | 2,499 (Final redemption, i.e. a+b-c) 136 (Tender offer) | Fair value of Tranche B MRI (in thousands of €) | | | | |
| | | | | Tranche C Minimum Return Indemnification (issued in June 2024) | | | | | Final redemption scenario probability | | | | | | | | | | | | | | | (a) Probability-weighted present value of shortfall payment (in thousands of €) | | 741 (Final redemption) 0 (Tender offer) | | 1,160 (Final redemption) 43 (Tender offer) | (b) Probability-weighted fair value of tranche C warrants with MRI (in thousands of €) | | | | | (c) Probability-weighted fair value of tranche C warrants without MRI (in thousands of €) | | | | | Total fair value of MRI (in thousands of €) | | 475 (Final redemption, i.e. a+b-c) 0 (Tender offer) | | 941 (Final redemption, i.e. a+b-c) 43 (Tender offer) | Fair value of Tranche C MRI (in thousands of €) | | | | |
The main data and assumptions are the following: | | | | | | | Kreos/Claret Tranche A-B BSA - August 2023 | | AS OF AUGUST 22, 2023 (Tranche A-B) | | | | | Number of outstanding BSA | | | | | | | | | | | | | | | | | | | | | | | 19/08/2030 (expiry) 18/02/2027 (tender offer) | | 19/08/2030 (expiry) 18/02/2027 (tender offer) | | 19/08/2030 (expiry) 18/02/2027 (tender offer) | 7-year expiry scenario probability | | | | | | | | | 71.9% (expiry) 65.2% (tender offer) | | 59.5% (expiry) 64.9% (tender offer) | | 44.3% (expiry) 44.3% (tender offer) | | | | | | | | | | | | | | 2.9% (expiry) 2.9% (tender offer) | Fair value of issued Kreos/Claret Tranche A-B BSA | | | | | | |
| | | | | | | Kreos/Claret Tranche C BSA - November 2023 | | | | | | | Number of outstanding BSA | | | | | | | of which, number of conditional BSA | | | | | | | | | | | | | | | | | | | | | | | 01/11/2030 (expiry) 18/02/2027 (tender offer) | | 01/11/2030 (expiry) 18/02/2027 (tender offer) | | 01/11/2030 (expiry) 18/02/2027 (tender offer) | 7-year expiry scenario probability | | | | | | | Probability of Drawdown of Tranche C credit facility | | | | | | | | | 67.3% (expiry) 64.3% (tender offer) | | 67.4% (expiry) 64.9% (tender offer) | | 44.3% (expiry) 44.3% (tender offer) | | | | | | | | | | | | | | 2.9% (expiry) 2.9% (tender offer) | Fair value of issued Kreos/Claret Tranche C BSA | | | | | | |
|
| Disclosure of main data and assumptions used for the measurement of convertible loan notes |
The main data and assumptions are the following: | | | | | | | Heights convertible notes - August 2023 | | | | | | | Number of outstanding notes | | | | | | | Original principal amount (in thousands of €) | | | | | | | | | | | | | | Conversion price per share | | | | | | | | | | | | | | | | 24/08/2025 (put event) 24/08/2027 (HTM/voluntary conversion) | | 24/08/2025 (put event) 24/08/2027 (HTM/voluntary conversion) | | 24/08/2025 (put event) 24/08/2027 (HTM/voluntary conversion) | Held to maturity / voluntary conversion scenario probability | | | | | | | | | | | | | | Early redemption amount (put event) | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fair value of Heights convertible notes (in thousands of €) | | | | | | |
|
| Disclosure of conditional advances |
Conditional advances as of December 31, 2023, 2024 and 2025 are as follows: | | | | | | (amounts in thousands of euros) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total conditional advances | | | | | |
|
| Disclosure of variation in lease liabilities |
The variations in lease liabilities are set forth below: | | (amounts in thousands of euros) | | | | | | | | | | | | | | | | | | | | | |
|
| Disclosure of reconciliation of liabilities arising from financing activities |
Changes in financial liabilities, excluding derivative instruments, are presented below as of December 31, 2023, 2024 and 2025: | | | | | | | | | | | | | | | | | | | | (Amounts in thousands of euros) | | | | | | | | | | | | | | | | | | | | FINANCIAL LIABILITIES (excluding derivatives instruments) | | | | | Kreos/ Claret convertible notes (OCABSA) | | Kreos & Claret bond loans | | Heights convertible notes | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Non-cash changes: classification of embedded derivatives as separate derivative financial instruments | | | | | | | | | | | | | | | | | | | | Non-cash changes: (gain)/ loss on recognition or derecognition | | | | | | | | | | | | | | | | | | | | Non-cash changes: interest expense and other | | | | | | | | | | | | | | | | | | | | Non-cash changes: recognition of earn-out liability | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | (Amounts in thousands of euros) | | | | | | | | | | | | | | | | | | | | FINANCIAL LIABILITIES (excluding derivatives instruments) | | | | | Kreos/ Claret convertible notes (OCABSA) | | Kreos & Claret bond loans | | Heights convertible notes | | | | | | | | | | | Non-cash changes: amortized cost | | | | | | | | | | | | | | | | | | | | Non-cash changes: other fair value remeasurement | | | | | | | | | | | | | | | | | | | | Non cash changes: additional leases | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Non-cash changes: classification of embedded | | | | | | | | | | | | | | | | | | | | Non-cash changes: (gain)/ loss on recognition or | | | | | | | | | | | | | | | | | | | | Non-cash changes: interest expense and other | | | | | | | | | | | | | | | | | | | | Non-cash changes: amortized cost remeasurement | | | | | | | | | | | | | | | | | | | | Non-cash changes: other fair value remeasurement | | | | | | | | | | | | | | | | | | | | Non-cash changes : subsidies | | | | | | | | | | | | | | | | | | | | Non cash changes: additional leases | | | | | | | | | | | | | | | | | | | | Non cash changes : Effect of the change in foreign | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Non-cash changes: (gain)/ loss on recognition or derecognition | | | | | | | | | | | | | | | | | | | | Non-cash changes: interest expense and other | | | | | | | | | | | | | | | | | | | | Non-cash changes: amortized cost remeasurement | | | | | | | | | | | | | | | | | | | | Non-cash changes: other fair value remeasurement | | | | | | | | | | | | | | | | | | | | Non-cash changes: conversion into shares | | | | | | | | | | | | | | | | | | | | Non cash changes: additional leases | | | | | | | | | | | | | | | | | | | | Non cash changes : Effect of the change in foreign currency exchange rates | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
| Disclosure of changes in derivative instruments |
Changes in derivative instruments, are presented below as of December 31, 2023, 2024 and 2025 : | | | | | | | | | | | | (amounts in thousands of euros) | | | | | | | | | Kreos/Claret Minimal Return Indemnifications | | | DERIVATIVE FINANCIAL INSTRUMENTS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (+) Increase in fair value | | | | | | | | | | | | (-) Decrease in fair value | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (+) Increase in fair value | | | | | | | | | | | | (-) Decrease in fair value | | | | | | | | | | | | | | | | | | | | | | | | (+) Increase in fair value | | | | | | | | | | | | (-) Decrease in fair value | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
| Disclosure of remaining contractual maturities of derivative financial liabilities |
The following are the remaining contractual maturities of financial liabilities as of December 31, 2023, 2024 and 2025. The amounts are gross and undiscounted, and include contractual interest payments. | | | | | | | | | | | | | (amounts in thousands of euros) | | | CURRENT AND NON-CURRENT FINANCIAL LIABILITIES | | | | | | | | | | | | | | | | | | | | Heights convertible notes | | | | | | | | | | | | | Kreos/Claret convertible notes (OCABSA) | | | | | | | | | | | | | | | | | | | | | | | | | | Conditional advances Bpifrance | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total financial liabilities | | | | | | | | | | | | |
| | | | | | | | | | | | | (amounts in thousands of euros) | | | CURRENT AND NON-CURRENT FINANCIAL LIABILITIES | | | | | | | | | | | | | | | | | | | | Heights convertible notes | | | | | | | | | | | | | Kreos/Claret convertible notes (OCABSA) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total financial liabilities | | | | | | | | | | | | |
| | | | | | | | | | | | (amounts in thousands of euros) | | CURRENT AND NON-CURRENT FINANCIAL LIABILITIES | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total financial liabilities | | | | | | | | | | | |
|
| Disclosure of remaining contractual maturities of non-derivative financial liabilities |
The following are the remaining contractual maturities of financial liabilities as of December 31, 2023, 2024 and 2025. The amounts are gross and undiscounted, and include contractual interest payments. | | | | | | | | | | | | | (amounts in thousands of euros) | | | CURRENT AND NON-CURRENT FINANCIAL LIABILITIES | | | | | | | | | | | | | | | | | | | | Heights convertible notes | | | | | | | | | | | | | Kreos/Claret convertible notes (OCABSA) | | | | | | | | | | | | | | | | | | | | | | | | | | Conditional advances Bpifrance | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total financial liabilities | | | | | | | | | | | | |
| | | | | | | | | | | | | (amounts in thousands of euros) | | | CURRENT AND NON-CURRENT FINANCIAL LIABILITIES | | | | | | | | | | | | | | | | | | | | Heights convertible notes | | | | | | | | | | | | | Kreos/Claret convertible notes (OCABSA) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total financial liabilities | | | | | | | | | | | | |
| | | | | | | | | | | | (amounts in thousands of euros) | | CURRENT AND NON-CURRENT FINANCIAL LIABILITIES | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Total financial liabilities | | | | | | | | | | | |
|